COSCIENS Biopharma Inc.
CSCIF
$4.98
-$0.32-6.04%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.14M | 1.89M | 1.77M | 1.48M | 2.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.14M | 1.89M | 1.77M | 1.48M | 2.42M |
| Cost of Revenue | 1.41M | 1.10M | 1.16M | 938.00K | 1.66M |
| Gross Profit | 1.74M | 793.00K | 609.00K | 545.00K | 753.00K |
| SG&A Expenses | 1.18M | 1.35M | 2.40M | 2.10M | 2.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.72M | 2.62M | 4.15M | 3.57M | 4.30M |
| Operating Income | 422.00K | -730.00K | -2.39M | -2.08M | -1.88M |
| Income Before Tax | -202.00K | -183.00K | -2.17M | -1.82M | -2.27M |
| Income Tax Expenses | -- | -- | 10.00K | -- | 2.00K |
| Earnings from Continuing Operations | -202.00K | -183.00K | -2.18M | -1.82M | -2.27M |
| Earnings from Discontinued Operations | -- | 10.94M | -- | -- | -427.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -202.00K | 10.76M | -2.18M | -1.82M | -2.70M |
| EBIT | 422.00K | -730.00K | -2.39M | -2.08M | -1.88M |
| EBITDA | 759.00K | -389.00K | -4.46M | -1.80M | -1.60M |
| EPS Basic | -0.19 | 10.27 | -2.06 | -1.72 | -2.57 |
| Normalized Basic EPS | -0.12 | -0.11 | -1.28 | -0.93 | -1.35 |
| EPS Diluted | -0.19 | 10.27 | -2.06 | -1.72 | -2.57 |
| Normalized Diluted EPS | -0.12 | -0.11 | -1.28 | -0.93 | -1.35 |
| Average Basic Shares Outstanding | 1.05M | 1.05M | 1.06M | 1.06M | 1.05M |
| Average Diluted Shares Outstanding | 1.05M | 1.05M | 1.06M | 1.06M | 1.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |